Crawford & Company (ESPR) compared with its closest peers (ARDX, ARQT, AVIR, MNKD, NATR). Peer set by Pharmaceutical Products; 10 comparable drugmakers. First-party data.
Ardelyx, Arcutis Biotherapeutics, Atea Pharmaceuticals, MannKind, Nature's Sunshine Products, Mirum Pharmaceuticals, Ironwood Pharmaceuticals, Rigel Pharmaceuticals, Xeris Biopharma and Organogenesis share Esperion Therapeutics's sub-industry, pharmaceutical makers.
| Company | Market Cap | P/E |
|---|---|---|
| Ardelyx, Inc. (ARDX) | $968.09M | -22.4 |
| Arcutis Biotherapeutics, Inc. (ARQT) | $3.15B | -223.4 |
| Atea Pharmaceuticals, Inc. (AVIR) | $434.71M | -1.8 |
| MannKind Corporation (MNKD) | $1.33B | 283.0 |
| Nature's Sunshine Products, Inc. (NATR) | $252.32M | 13.2 |
| Mirum Pharmaceuticals, Inc. (MIRM) | $5.87B | -168.0 |
| Ironwood Pharmaceuticals, Inc. (IRWD) | $708.05M | 4.1 |
| Rigel Pharmaceuticals, Inc. (RIGL) | $857.22M | 13.7 |
| Xeris Biopharma Holdings, Inc. (XERS) | $1.50B | — |
| Organogenesis Holdings Inc. (ORGO) | $231.61M | 34.5 |
ESPR overview · ESPR earnings · ESPR financials · ESPR KPIs · ESPR documents · ESPR ownership
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.